Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Scientific Activity In biochemical and cell models, 5-AMINO-1MQ inhibits NNMT, reducing methyl transfer from S-adenosylmethionine to nicotinamide and altering downstream methyl-donor and nicotinamide metabolite pools
Pull out the needle after injecting the right dosage
What Are Peptides, Exactly
Tilt it gently
Novartis Pluvicto established radioligand therapy as a commercial reality (2022+): Lutetium-177 PSMA-617 (Pluvicto) for metastatic castration-resistant prostate cancer achieved rapid adoption post-2022 launch, validating the peptide receptor radionuclide therapy platform and creating a template for multiple follow-on radioligand therapy programmes
US$ 23.84
US$ 24.49
US$ 28.88
